Based on the NPM1-MRD results of AML patients, here we examined two different MFC-MRD analysis approaches to evaluate whether the selection/quantification of cells expressing aberrant lineage markers reflected residual disease. This evidence concerns the gene NPM1 and acute myeloid leukemia.